The University of Texas MD Anderson Cancer Center and Royal Philips are providing oncologists with evidence-based therapy and clinical trial guidance through Philips’ oncology informatics solutions and MD Anderson’s Precision Oncology Decision Support system.
This collaboration will allow physicians around the world to personalize therapy based on the patient’s genomic profile, with the aim of improving patient care.
MD Anderson developed the PODS system as an evidence-based tool to facilitate therapeutic decision-making at the point of care. The system provides actionable clinical information, including approved therapies and available clinical trials, based upon genetic alterations within the tumor. Through the Philips solutions, clinicians receive a unified view of therapies and clinical trials in the context of their patient’s unique tumor, helping them make an evidence-based decision for their patient’s treatment.
Philips and MD Anderson aim to help pathologists and oncologists serve their patients and provide them with therapeutic options and relevant clinical trials based on tumor markers.
